checkAd

     120  0 Kommentare Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR - Seite 3

    CONTACTS:

    For Monopar Therapeutics Inc.:
    Investor Relations:
    Kim R. Tsuchimoto
    Chief Financial Officer
    kimtsu@monopartx.com

    For NorthStar Medical Radioisotopes, LLC 
    Investor Relations:
    Paul Estrem
    Senior Vice President and Chief Financial Officer
    pestrem@northstarnm.com

    Corporate:
    Lisa Holst
    Vice President Sales and Marketing
    678-471-9027
    lholst@northstarnm.com

    Media:
    Priscilla Harlan
    781-799-7917
    pharlan@shiningrockllc.com

    Lesen Sie auch

     



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR - Seite 3 CHICAGO and BELOIT, Wis., June 30, 2020 (GLOBE NEWSWIRE) - Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today that a provisional patent application entitled “Precision …